Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 4 (2007), Issue 7 (July)

1. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.
   J Thorac Oncol, 2(7): S94-100. [Abstract] [Full-text]
2. Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers.
   J Thorac Oncol, 2(7): S128-35. [Abstract] [Full-text]
3. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
   J Thorac Oncol, 2(7): S125-7. [Abstract] [Full-text]
4. Radiographic response and clinical toxicity following SBRT for stage I lung cancer.
   J Thorac Oncol, 2(7): S118-24. [Abstract] [Full-text]
5. A Japan clinical oncology group trial for stereotactic body radiation therapy of non-small cell lung cancer.
   J Thorac Oncol, 2(7): S115-7. [Abstract] [Full-text]
6. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer.
   J Thorac Oncol, 2(7): S101-12. [Abstract] [Full-text]
7. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
   J Clin Oncol, 25(19): 2747-54. [Abstract] [Full-text]
8. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
   J Clin Oncol, 25(19): 2741-6. [Abstract] [Full-text]
9. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
   J Clin Oncol, 25(19): 2735-40. [Abstract] [Full-text]
10. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.
    J Clin Oncol, 25(19): 2727-34. [Abstract] [Full-text]
11. Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.
    J Cell Physiol, 212(3): 710-6. [Abstract] [Full-text]
12. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.
    Int J Cancer, 121(4): 863-70. [Abstract] [Full-text]
13. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer.
    Int J Cancer, 121(4): 895-900. [Abstract] [Full-text]
14. Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.
    Int J Cancer, 121(5): 1162-7. [Abstract] [Full-text]
15. Fruit and vegetable consumption and lung cancer risk: updated information from the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Int J Cancer, 121(5): 1103-14. [Abstract] [Full-text]
16. Homeobox gene HOP has a potential tumor suppressive activity in human lung cancer.
    Int J Cancer, 121(5): 1021-7. [Abstract] [Full-text]
17. Targeting mTOR signaling in lung cancer.
    Crit Rev Oncol Hematol, 63(2): 172-82. [Abstract] [Full-text]
18. Computational modeling and functional analysis of Herpes simplex virus type-1 thymidine kinase and Escherichia coli cytosine deaminase fusion protein.
    Biochem Biophys Res Commun, 360(1): 46-50. [Abstract] [Full-text]
19. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    JAMA, 298(1): 70-82. [Abstract] [Full-text]
20. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells.
    Stem Cells, 25(7): 1618-26. [Abstract] [Full-text]
21. Indole-3-carbinol inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo(a)pyrene-induced lung tumorigenesis in A/J mice and modulates carcinogen-induced alterations in protein levels.
    Cancer Res, 67(13): 6502-11. [Abstract] [Full-text]
22. The role of protein binding in induction of apoptosis by phenethyl isothiocyanate and sulforaphane in human non-small lung cancer cells.
    Cancer Res, 67(13): 6409-16. [Abstract] [Full-text]
23. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
    Cancer Res, 67(13): 6325-32. [Abstract] [Full-text]
24. Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy.
    Cancer Res, 67(13): 6293-303. [Abstract] [Full-text]
25. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells.
    Cancer Res, 67(13): 6278-85. [Abstract] [Full-text]
26. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
    Cancer Res, 67(13): 6253-62. [Abstract] [Full-text]
27. FRA-1 proto-oncogene induces lung epithelial cell invasion and anchorage-independent growth in vitro, but is insufficient to promote tumor growth in vivo.
    Cancer Res, 67(13): 6204-11. [Abstract] [Full-text]
28. Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner.
    Cancer Res, 67(13): 6053-63. [Abstract] [Full-text]
29. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1.
    Cancer Res, 67(13): 6007-11. [Abstract] [Full-text]
30. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer.
    Cancer Res, 67(13): 6520-7. [Abstract] [Full-text]
31. Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer.
    Oncogene, 26(32): 4730-7. [Abstract] [Full-text]
32. Assessment of a chemically induced model of lung squamous cell carcinoma in mice by 18F-FDG small-animal PET.
    Nucl Med Commun, 28(8): 647-52. [Abstract] [Full-text]
33. Antioxidative and prooxidative effects of quercetin on A549 cells.
    Cell Biol Int, 31(10): 1245-50. [Abstract] [Full-text]
34. Predicting lung radiotherapy-induced pneumonitis using a model combining parametric Lyman probit with nonparametric decision trees.
    Int J Radiat Oncol Biol Phys, 68(4): 1212-21. [Abstract] [Full-text]
35. Dose as a function of lung volume and planned treatment volume in helical tomotherapy intensity-modulated radiation therapy-based stereotactic body radiation therapy for small lung tumors.
    Int J Radiat Oncol Biol Phys, 68(4): 1229-37. [Abstract] [Full-text]
36. Estimating the magnitude and field-size dependence of radiotherapy-induced mortality and tumor control after postoperative radiotherapy for non-small-cell lung cancer: calculations from clinical trials.
    Int J Radiat Oncol Biol Phys, 68(4): 1047-52. [Abstract] [Full-text]
37. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography.
    Int J Radiat Oncol Biol Phys, 68(4): 1036-46. [Abstract] [Full-text]
38. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
    J Clin Oncol, 25(21): 3124-9. [Abstract] [Full-text]
39. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
    J Clin Oncol, 25(21): 3116-23. [Abstract] [Full-text]
40. Immunolocalization and cell expression of lung resistance-related protein (LRP) in normal and tumoral human respiratory cells.
    J Histochem Cytochem, 55(8): 773-82. [Abstract] [Full-text]
41. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol, 60(4): 601-7. [Abstract] [Full-text]
42. Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer.
    Cancer Chemother Pharmacol, 60(4): 495-501. [Abstract] [Full-text]
43. Cerebral metastasis and other central nervous system complications of pleuropulmonary blastoma.
    Pediatr Blood Cancer, 49(3): 266-73. [Abstract] [Full-text]
44. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma.
    Ann Thorac Surg, 84(2): 702-7. [Abstract] [Full-text]
45. Comparison of on-pump or off-pump coronary artery revascularization with lung resection.
    Ann Thorac Surg, 84(2): 504-9. [Abstract] [Full-text]
46. Quality of life before and after major lung resection for lung cancer: a prospective follow-up analysis.
    Ann Thorac Surg, 84(2): 410-6. [Abstract] [Full-text]
47. Castleman's disease mimicking intrapulmonary malignancy.
    Ann Thorac Surg, 84(2): e6-7. [Abstract] [Full-text]
48. Polyphosphate blocks tumour metastasis via anti-angiogenic activity.
    Biochem J, 406(1): 49-55. [Abstract] [Full-text]
49. Reduced lung cancer deaths attributable to decreased tobacco use in Massachusetts.
    Cancer Causes Control, 18(8): 833-8. [Abstract] [Full-text]
50. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
    Cancer Immunol Immunother, 56(10): 1637-44. [Abstract] [Full-text]

© 2004-2010 Lung Cancer Research Today. All Rights Reserved.